Regulation is often utilized as a key demand driver for non-toxic alternatives; however, the lack of regulation and increased litigation risk in the herbicide industry creates both a unique risk landscape and an investment opportunity. Such legacy chemicals such as glyphosate, atrazine, paraquat, and dicamba have documented carcinogenicity, endocrine, and neurological risk effects, and have collectively driven billions of dollars in litigation exposure for their manufacturers, most notably Bayer's over $10 billion in existing Roundup settlements.